{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T05:06:09Z","timestamp":1794373569897,"version":"4.9.0"},"reference-count":77,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    The molecular landscape of numerous human malignancies has been elucidated since the advances in sequencing techniques. However, unlike their cutaneous counterparts, which have a higher incidence and more affected patients as study subjects, conjunctival melanocytic neoplasms are less studied, with evidence mainly restricted to case reports or case series. This review aims to summarize and update findings on genetic alterations in conjunctival melanocytic lesions based on the diagnoses listed in the fifth edition of the World Health Organization classification of the tumors of the eye. These include conjunctival common nevus, conjunctival blue nevus, conjunctival WNT-activated deep penetrating\/plexiform melanocytoma (nevus), conjunctival melanocytic intraepithelial lesions, and conjunctival melanoma. We also review the role of genetic alterations in the development and progression of conjunctival melanoma. Furthermore, we compare the genetic alterations of conjunctival melanoma with those of cutaneous melanoma and discuss specific targeted therapies such as\n                    <jats:italic toggle=\"yes\">BRAF<\/jats:italic>\n                    inhibitors, MEK inhibitors, and immunotherapies for localized advanced or metastatic conjunctival melanoma. In conclusion, this article reviews recent advances in genetic alterations and associated treatment strategies for conjunctival melanocytic lesions, including benign, premalignant, and malignant diseases. The similarities between conjunctival and cutaneous melanoma may shed a light on future studies and clinical trials focused on conjunctival melanoma.\n                  <\/jats:p>","DOI":"10.4103\/tjo.tjo-d-24-00109","type":"journal-article","created":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T02:00:09Z","timestamp":1741312809000},"page":"26-33","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Current findings of genetic alterations and associated targeted therapies of conjunctival melanocytic neoplasms"],"prefix":"10.4103","volume":"15","author":[{"given":"Lei-Chi","family":"Wang","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Taipei Veterans General Hospital, Taipei, Taiwan"},{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Chih","family":"Tsai","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tai-Chi","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan"},{"name":"Department of Ophthalmology, Taipei Veterans General Hospital, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narsing A.","family":"Rao","sequence":"additional","affiliation":[{"name":"USC Roski Eye Institute, Department of Ophthalmology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"key":"R1-20250320","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.3390\/ijms22115784","article-title":"Molecular genetics of conjunctival melanoma and prognostic value of TERT promoter mutation analysis","volume":"22","author":"van Poppelen","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R2-20250320","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1002\/(SICI)1097-0142(19981015)83:8<1664::AID-CNCR23>3.0.CO;2-G","article-title":"The National Cancer Data Base report on cutaneous and noncutaneous melanoma:A summary of 84,836 cases from the past decade. The American College of Surgeons Commission on Cancer and the American Cancer Society","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"R3-20250320","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1002\/cncr.20866","article-title":"Incidence of noncutaneous melanomas in the U. S.","volume":"103","author":"McLaughlin","year":"2005","journal-title":"Cancer"},{"key":"R4-20250320","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1167\/iovs.04-1449","article-title":"T1799A BRAF mutations in conjunctival melanocytic lesions","volume":"46","author":"Goldenberg-Cohen","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R5-20250320","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/aos.13007","article-title":"BRAF mutations in conjunctival melanoma:Investigation of incidence, clinicopathological features, prognosis and paired premalignant lesions","volume":"94","author":"Larsen","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"R6-20250320","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1167\/iovs.17-22517","article-title":"BRAF, NRAS, and GNAQ Mutations in conjunctival melanocytic nevi","volume":"59","author":"Francis","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R7-20250320","doi-asserted-by":"crossref","first-page":"e641","DOI":"10.1111\/aos.12166","article-title":"C-Kit SCF receptor (CD117) expression and KIT gene mutation in conjunctival pigmented lesions","volume":"91","author":"Alessandrini","year":"2013","journal-title":"Acta Ophthalmol"},{"key":"R8-20250320","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1080\/13816810.2022.2039719","article-title":"Diagnosis of the origin of an epibulbar melanocytic tumor with molecular genomics","volume":"43","author":"Gonzalez-H Leon","year":"2022","journal-title":"Ophthalmic Genet"},{"key":"R9-20250320","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1159\/000442352","article-title":"Investigation of somatic GNAQ, GNA11, BAP1 and SF3B1 mutations in ophthalmic melanocytomas","volume":"2","author":"Francis","year":"2016","journal-title":"Ocul Oncol Pathol"},{"key":"R10-20250320","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1038\/ng1412","article-title":"Effects of G-protein mutations on skin color","volume":"36","author":"Van Raamsdonk","year":"2004","journal-title":"Nat Genet"},{"key":"R11-20250320","doi-asserted-by":"crossref","first-page":"e6833","DOI":"10.1371\/journal.pone.0006833","article-title":"Mutational profile of GNAQQ209 in human tumors","volume":"4","author":"Lamba","year":"2009","journal-title":"PLoS One"},{"key":"R12-20250320","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1056\/NEJMoa1000584","article-title":"Mutations in GNA11 in uveal melanoma","volume":"363","author":"Van Raamsdonk","year":"2010","journal-title":"N Engl J Med"},{"key":"R13-20250320","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s00401-009-0611-3","article-title":"Activating mutations of the GNAQ gene:A frequent event in primary melanocytic neoplasms of the central nervous system","volume":"119","author":"K\u00fcsters-Vandevelde","year":"2010","journal-title":"Acta Neuropathol"},{"key":"R14-20250320","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1016\/j.oooo.2012.09.001","article-title":"BRAF and GNAQ mutations in melanocytic tumors of the oral cavity","volume":"114","author":"Cohen","year":"2012","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"R15-20250320","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1159\/000504966","article-title":"Histopathological and molecular features of a conjunctival caruncular deep penetrating nevus","volume":"6","author":"van Ipenburg","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"R16-20250320","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.pathol.2023.01.008","article-title":"Conjunctival combined deep penetrating naevus:A clinicopathological report","volume":"55","author":"Hohnen","year":"2023","journal-title":"Pathology"},{"key":"R17-20250320","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1136\/bjophthalmol-2019-314807","article-title":"Combined deep penetrating nevi of the conjunctiva are relatively common lesions characterised by BRAFV600E mutation and activation of the beta catenin pathway:A clinicopathological analysis of 34 lesions","volume":"104","author":"\u0160ekoranja","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R18-20250320","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1038\/s41379-022-01026-6","article-title":"Towards diagnostic criteria for malignant deep penetrating melanocytic tumors using single nucleotide polymorphism array and next-generation sequencing","volume":"35","author":"Ebbelaar","year":"2022","journal-title":"Mod Pathol"},{"key":"R19-20250320","doi-asserted-by":"crossref","first-page":"6024","DOI":"10.1167\/iovs.14-14901","article-title":"Prevalence and implications of TERT promoter mutation in uveal and conjunctival melanoma and in benign and premalignant conjunctival melanocytic lesions","volume":"55","author":"Koopmans","year":"2014","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R20-20250320","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1136\/bjophthalmol-2020-317405","article-title":"Prognostic value of TERT promoter mutations in conjunctival melanomas in addition to clinicopathological features","volume":"105","author":"van Ipenburg","year":"2021","journal-title":"Br J Ophthalmol"},{"key":"R21-20250320","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1158\/1078-0432.CCR-13-0163","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas","volume":"19","author":"Griewank","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R22-20250320","doi-asserted-by":"crossref","first-page":"58021","DOI":"10.18632\/oncotarget.10770","article-title":"Targeting of the MAPK and AKT pathways in conjunctival melanoma shows potential synergy","volume":"8","author":"Cao","year":"2017","journal-title":"Oncotarget"},{"key":"R23-20250320","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1001\/jamaophthalmol.2015.3200","article-title":"ARetrospective review of conjunctival melanoma presentation, Treatment, and outcome and an investigation of features associated with BRAF mutations","volume":"133","author":"Larsen","year":"2015","journal-title":"JAMA Ophthalmol"},{"key":"R24-20250320","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/path.5094","article-title":"Overexpression of EZH2 in conjunctival melanoma offers a new therapeutic target","volume":"245","author":"Cao","year":"2018","journal-title":"J Pathol"},{"key":"R25-20250320","doi-asserted-by":"crossref","first-page":"12988","DOI":"10.3390\/ijms241612988","article-title":"ATRX loss in the development and prognosis of conjunctival Melanoma","volume":"24","author":"van Ipenburg","year":"2023","journal-title":"Int J Mol Sci"},{"key":"R26-20250320","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000520953","article-title":"Single time frame overview of the genetic changes in conjunctival melanoma from intraepithelial disease to invasive melanoma:A study of 4 exenteration specimens illustrating the potential role of cyclin D1","volume":"8","author":"Mudhar","year":"2022","journal-title":"Ocul Oncol Pathol"},{"key":"R27-20250320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.humpath.2023.02.002","article-title":"PRAME expression by immunohistochemistry and reverse transcription quantitative PCR in conjunctival melanocytic lesions-a comprehensive clinicopathologic study of 202 cases and correlation of cytogenetics with PRAME expression in challenging conjunctival melanocytic lesions","volume":"134","author":"Mudhar","year":"2023","journal-title":"Hum Pathol"},{"key":"R28-20250320","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ophtha.2022.01.016","article-title":"Mutational landscape and outcomes of conjunctival melanoma in 101 patients","volume":"129","author":"Lally","year":"2022","journal-title":"Ophthalmology"},{"key":"R29-20250320","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1001\/jamaophthalmol.2017.4837","article-title":"Molecular characteristics of conjunctival melanoma using whole-exome sequencing","volume":"135","author":"Swaminathan","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R30-20250320","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/jamaophthalmol.2019.4237","article-title":"Integrative exome and transcriptome analysis of conjunctival melanoma and its potential application for personalized therapy","volume":"137","author":"Demirci","year":"2019","journal-title":"JAMA Ophthalmol"},{"key":"R31-20250320","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1038\/s41416-018-0046-5","article-title":"NF1 mutations in conjunctival melanoma","volume":"118","author":"Scholz","year":"2018","journal-title":"Br J Cancer"},{"issue":"Suppl 115","key":"R32-20250320","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/aos.14536","article-title":"Molecular biology in conjunctival melanoma and the relationship to mucosal melanoma","volume":"98","author":"Mikkelsen","year":"2020","journal-title":"Acta Ophthalmol"},{"key":"R33-20250320","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1167\/iovs.04-0093","article-title":"BRAF mutations in conjunctival melanoma","volume":"45","author":"Gear","year":"2004","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R34-20250320","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/00008390-200412000-00003","article-title":"BRAF mutations are detectable in conjunctival but not uveal melanomas","volume":"14","author":"Spendlove","year":"2004","journal-title":"Melanoma Res"},{"key":"R35-20250320","doi-asserted-by":"crossref","first-page":"5598","DOI":"10.1167\/iovs.10-6934","article-title":"Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes","volume":"52","author":"Lake","year":"2011","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R36-20250320","doi-asserted-by":"crossref","first-page":"6821","DOI":"10.1158\/1078-0432.CCR-08-0575","article-title":"KIT gene mutations and copy number in melanoma subtypes","volume":"14","author":"Beadling","year":"2008","journal-title":"Clin Cancer Res"},{"key":"R37-20250320","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1136\/bjophthalmol-2014-305730","article-title":"Prognostic factors for conjunctival melanoma:A study in ethnic Chinese patients","volume":"99","author":"Sheng","year":"2015","journal-title":"Br J Ophthalmol"},{"key":"R38-20250320","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/bjc.2013.312","article-title":"TERT promoter mutations in ocular melanoma distinguish between conjunctival and uveal tumours","volume":"109","author":"Griewank","year":"2013","journal-title":"Br J Cancer"},{"key":"R39-20250320","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejca.2022.01.008","article-title":"Genetic characterization of advanced conjunctival melanoma and response to systemic treatment","volume":"166","author":"Lodde","year":"2022","journal-title":"Eur J Cancer"},{"key":"R40-20250320","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/j.survophthal.2020.09.004","article-title":"Clinical treatment options for early-stage and advanced conjunctival melanoma","volume":"66","author":"Zeng","year":"2021","journal-title":"Surv Ophthalmol"},{"key":"R41-20250320","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1038\/s41379-022-01138-z","article-title":"Identification of fusions with potential clinical significance in melanoma","volume":"35","author":"Moran","year":"2022","journal-title":"Mod Pathol"},{"key":"R42-20250320","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/bjo-2023-324306","article-title":"Genetic landscape and prognosis of conjunctival melanoma in Chinese patients","volume":"108","author":"Shi","year":"2024","journal-title":"Br J Ophthalmol"},{"key":"R43-20250320","first-page":"109","article-title":"Conjunctival tumors:Review of clinical features, risks, biomarkers, and outcomes \u2013The 2017 J. Donald M. Gass Lecture","volume":"6","author":"Shields","year":"2017","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"key":"R44-20250320","doi-asserted-by":"crossref","first-page":"5231","DOI":"10.3390\/ijms21155231","article-title":"Genetic biomarkers in melanoma of the ocular region:What the medical oncologist should know","volume":"21","author":"Bol","year":"2020","journal-title":"Int J Mol Sci"},{"key":"R45-20250320","doi-asserted-by":"crossref","first-page":"5447","DOI":"10.3390\/ijms20215447","article-title":"Conjunctival melanoma:Genetic and epigenetic insights of a distinct type of melanoma","volume":"20","author":"Rossi","year":"2019","journal-title":"Int J Mol Sci"},{"key":"R46-20250320","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/exd.14287","article-title":"Genetic drivers of non-cutaneous melanomas:Challenges and opportunities in a heterogeneous landscape","volume":"31","author":"Vergara","year":"2022","journal-title":"Exp Dermatol"},{"key":"R47-20250320","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/nature08658","article-title":"Acomprehensive catalogue of somatic mutations from a human cancer genome","volume":"463","author":"Pleasance","year":"2010","journal-title":"Nature"},{"key":"R48-20250320","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1038\/jhg.2015.152","article-title":"UV light signature in conjunctival melanoma;not only skin should be protected from solar radiation","volume":"61","author":"Rivolta","year":"2016","journal-title":"J Hum Genet"},{"key":"R49-20250320","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/nature22071","article-title":"Whole-genome landscapes of major melanoma subtypes","volume":"545","author":"Hayward","year":"2017","journal-title":"Nature"},{"key":"R50-20250320","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1016\/j.ajhg.2016.09.008","article-title":"Comprehensive genetic landscape of uveal melanoma by whole-genome sequencing","volume":"99","author":"Royer-Bertrand","year":"2016","journal-title":"Am J Hum Genet"},{"key":"R51-20250320","doi-asserted-by":"crossref","first-page":"4624","DOI":"10.18632\/oncotarget.6614","article-title":"Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4","volume":"7","author":"Johansson","year":"2016","journal-title":"Oncotarget"},{"key":"R52-20250320","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.ccell.2017.07.003","article-title":"Integrative analysis identifies four molecular and clinical subsets in uveal melanoma","volume":"32","author":"Robertson","year":"2017","journal-title":"Cancer Cell"},{"key":"R53-20250320","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/s41467-017-02428-w","article-title":"Punctuated evolution of canonical genomic aberrations in uveal melanoma","volume":"9","author":"Field","year":"2018","journal-title":"Nat Commun"},{"key":"R54-20250320","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1038\/s41467-020-16276-8","article-title":"Whole genome landscapes of uveal melanoma show an ultraviolet radiation signature in iris tumours","volume":"11","author":"Johansson","year":"2020","journal-title":"Nat Commun"},{"key":"R55-20250320","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.3390\/cancers11081133","article-title":"Atypical BRAF and NRAS mutations in mucosal melanoma","volume":"11","author":"Dumaz","year":"2019","journal-title":"Cancers (Basel)"},{"key":"R56-20250320","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1016\/S0161-6420(01)00782-5","article-title":"Patterns of regional and distant metastasis in patients with conjunctival melanoma:Experience at a cancer center over four decades","volume":"108","author":"Esmaeli","year":"2001","journal-title":"Ophthalmology"},{"key":"R57-20250320","doi-asserted-by":"crossref","first-page":"16163","DOI":"10.1002\/cam4.6273","article-title":"Clinical features and prognosis of patients with metastatic ocular and orbital melanoma:A bi-institutional study","volume":"12","author":"Liu","year":"2023","journal-title":"Cancer Med"},{"key":"R58-20250320","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s40257-019-00500-3","article-title":"Conjunctival Melanoma:Current treatments and future options","volume":"21","author":"Grimes","year":"2020","journal-title":"Am J Clin Dermatol"},{"key":"R59-20250320","doi-asserted-by":"crossref","first-page":"322","DOI":"10.4172\/2155-9570.1000322","article-title":"Conjunctival melanoma and BRAF inhibitor therapy","volume":"5","author":"Pahlitzsch","year":"2014","journal-title":"J Clin Exp Ophthalmol"},{"key":"R60-20250320","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000497473","article-title":"Dabrafenib and trametinib for BRAF-mutated conjunctival melanoma","volume":"6","author":"Kim","year":"2020","journal-title":"Ocul Oncol Pathol"},{"key":"R61-20250320","doi-asserted-by":"crossref","first-page":"6329","DOI":"10.1158\/1078-0432.CCR-13-2007","article-title":"Conjunctival melanomas harbor BRAF and NRAS mutations \u2013Letter","volume":"19","author":"Weber","year":"2013","journal-title":"Clin Cancer Res"},{"key":"R62-20250320","first-page":"1","article-title":"Systemic treatment of metastatic conjunctival melanoma","volume":"2017","author":"Pinto Torres","year":"2017","journal-title":"Case Rep Oncol Med"},{"key":"R63-20250320","doi-asserted-by":"crossref","first-page":"e114","DOI":"10.1097\/IOP.0000000000000833","article-title":"Conjunctival melanoma responsive to combined systemic BRAF\/MEK inhibitors","volume":"33","author":"Dagi Glass","year":"2017","journal-title":"Ophthalmic Plast Reconstr Surg"},{"key":"R64-20250320","doi-asserted-by":"crossref","first-page":"232","DOI":"10.3389\/fonc.2019.00232","article-title":"Dabrafenib and trametinib in BRAF mutant metastatic conjunctival melanoma","volume":"9","author":"Rossi","year":"2019","journal-title":"Front Oncol"},{"key":"R65-20250320","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1186\/s12885-016-2657-7","article-title":"A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib","volume":"16","author":"Maleka","year":"2016","journal-title":"BMC Cancer"},{"key":"R66-20250320","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.4103\/ijo.IJO_663_19","article-title":"Conjunctival melanoma with orbital invasion and liver metastasis managed with systemic immune checkpoint inhibitor therapy","volume":"67","author":"Chang","year":"2019","journal-title":"Indian J Ophthalmol"},{"key":"R67-20250320","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s40425-019-0555-7","article-title":"Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma:A clinical case series","volume":"7","author":"Finger","year":"2019","journal-title":"J Immunother Cancer"},{"key":"R68-20250320","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1001\/jamaophthalmol.2017.2279","article-title":"Pembrolizumab for recurrent conjunctival melanoma","volume":"135","author":"Kini","year":"2017","journal-title":"JAMA Ophthalmol"},{"key":"R69-20250320","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1001\/jamaophthalmol.2018.3488","article-title":"Immunotherapy with programmed cell death 1 inhibitors for 5 patients with conjunctival melanoma","volume":"136","author":"Sagiv","year":"2018","journal-title":"JAMA Ophthalmol"},{"key":"R70-20250320","first-page":"3399","article-title":"Population-based assessment of clinical characteristics predicting outcome of conjunctival melanoma in whites","volume":"43","author":"Tuomaala","year":"2002","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R71-20250320","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1136\/bjophthalmol-2019-313977","article-title":"Incidence trends of conjunctival malignant melanoma in Canada","volume":"104","author":"Ghazawi","year":"2020","journal-title":"Br J Ophthalmol"},{"key":"R72-20250320","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1001\/jamaophthalmol.2020.0531","article-title":"Incidence and survival of patients with conjunctival melanoma in Europe","volume":"138","author":"Virgili","year":"2020","journal-title":"JAMA Ophthalmol"},{"key":"R73-20250320","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/j.ajo.2007.10.022","article-title":"Population-based incidence of conjunctival melanoma in various races and ethnic groups and comparison with other melanomas","volume":"145","author":"Hu","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"R74-20250320","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1080\/08820538.2019.1620793","article-title":"Conjunctival melanoma in Asian Indians:A study of 42 patients","volume":"34","author":"Kaliki","year":"2019","journal-title":"Semin Ophthalmol"},{"key":"R75-20250320","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1167\/iovs.17-22376","article-title":"Conjunctival melanoma in Chinese patients:Local recurrence, metastasis, mortality, and comparisons with Caucasian patients","volume":"58","author":"Zhou","year":"2017","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"R76-20250320","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1186\/s12885-016-2747-6","article-title":"Racial differences in six major subtypes of melanoma:Descriptive epidemiology","volume":"16","author":"Wang","year":"2016","journal-title":"BMC Cancer"},{"key":"R77-20250320","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1001\/archdermatol.2008.609","article-title":"Acral lentiginous melanoma:Incidence and survival patterns in the United States, 1986-2005","volume":"145","author":"Bradford","year":"2009","journal-title":"Arch Dermatol"}],"container-title":["Taiwan Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T18:51:48Z","timestamp":1786647108000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/tjo.TJO-D-24-00109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":77,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.4103\/tjo.tjo-d-24-00109","relation":{},"ISSN":["2211-5056","2211-5072"],"issn-type":[{"value":"2211-5056","type":"print"},{"value":"2211-5072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-09-11","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-12-30","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}